Title

Improvement in patient global impression measures with upadacitinib with or without topical corticosteroids in moderate to severe atopic dermatitis: Results from placebo-controlled phase 3 studies

Document Type

Conference Proceeding

Publication Date

11-1-2021

Publication Title

Exp Dermatol

Abstract

Introduction: Atopic dermatitis (AD) is associated with symptoms that impact patients’ quality of life. We assessed improvements in patient global impression measures with upadacitinib (UPA) versus placebo (PBO) using data from three moderate-to-severe AD trials.

Methods: Patients (age 12-75 years) with moderate-to-severe AD were randomized 1:1:1 to once-daily UPA 15 mg, 30 mg, or PBO without concomitant topical corticosteroids (Measure Up 1 [NCT03569293], Measure Up 2 [NCT03607422]) or with concomitant topical corticosteroids (AD Up [NCT03568318]) for 16 weeks. Overall symptom severity, symptom improvement, and treatment satisfaction were assessed by the Patient Global Impression of Severity (PGIS), Patient Global Impression of Change (PGIC), and Patient Global Impression of Treatment (PGIT) questionnaires, respectively.

Results: On the PGIS, greater proportions of patients reported that their symptoms were “absent/minimal” with UPA 15 mg/30 mg versus PBO as early as the first post-baseline study visit (week 1 for Measure Up 1 and 2; week 2 for AD Up) and through to week 16 (Measure Up 1: 43.5%/59.6% versus 8.3%; Measure Up 2: 38.6%/53.1% versus 6.7%; AD Up: 42.9%/55.7% versus 9.3%; p < 0.001). Similarly, on the PGIC, greater proportions of patients reported that their disease was “much improved/very much improved” as early as week 1 (week 2 for AD Up) and through to week 16 (Measure Up 1: 70.0%/79.8% versus 19.7%; Measure Up 2: 66.3%/76.3% versus 15.8%; AD Up: 73.6%/82.3% versus 28.8%; p < 0.001). Treatment satisfaction results were consistent, with more patients reporting that they were “very satisfied/extremely satisfied” in the UPA 15 mg/30 mg arms versus PBO as early as week 1 (week 2 for AD Up) and through to week 16 (Measure Up 1: 54.3%/60.0% versus 12.3%; Measure Up 2: 47.6%/57.1% versus 10.4%; AD Up: 53.7%/64.7% versus 18.7%; p < 0.001).

Discussion: More patients reported no/minimal AD symptoms, much improved disease, and high levels of treatment satisfaction with UPA (15 mg or 30 mg) versus PBO, with or without concomitant topical corticosteroids, across all study visits throughout the 16-week period.

Volume

2021

Issue

30

First Page

16

Last Page

17

Share

COinS